Shandong Pharmaceutical Glass Co Ltd

The company maintains a strong liquidity position with a current ratio of 3.75, indicating a robust ability to meet short-term obligations. Its price-to-book ratio of 1.51 and price-to-tangible-book ratio of 1.51 suggest that the market values the company at a moderate premium to its equity. The debt-to-equity ratio of 0.01 reflects a conservative capital structure with minimal leverage. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 8.31% and a return on assets (ROA) of 6.87%, both of which are in line with industry norms for non-paper packaging firms. The gross profit margin of 31.0% (1386942710 / 4474018980) and operating margin of 18.7% (837960830 / 4474018980) indicate healthy profitability, though the net margin of 15.4% (689626040 / 4474018980) suggests some pressure from operating expenses. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of segmental or geographic diversification could expose the company to sector-specific or regional risks. Looking ahead, the company is projected to grow revenue by 5.2% in the current fiscal year and 3.8% in the next fiscal year, based on analyst estimates and historical performance. The mean price target of 23.05 CNY implies a potential upside of 21.8% from the current market price of 18.92 CNY. The risk assessment highlights a medium liquidity risk and a low dilution risk, with no significant dilution expected in the near term. The company has not issued new shares recently, and the diluted share count is equal to the basic share count, indicating no imminent pressure from share issuance. Recent filings and transcripts are not available in the provided data, so no specific events can be cited for the company's recent performance or strategic direction.